Immune checkpoint inhibitors (ICIs) have been changing the paradigm of cancer treatment.
However, immune-related adverse effects (irAEs) have also increased with the exponential …

Immune checkpoint inhibitors (ICIs) are a novel class of immunotherapy drugs that have
improved the treatment of a broad spectrum of cancers as metastatic melanoma, non-small …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Background Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has
emerged as an important toxicity among patients with cancer. Methods We collected data on …

Immune checkpoint inhibitors have dramatically improved cancer therapy for many patients.
These humanized monoclonal antibodies against various immune checkpoints (receptors …

Nephrotoxicity from cancer therapies is common and increasingly encountered in clinical
practice, such that the subfield of “onco-nephrology” has emerged. Conventional …

Since their introduction into clinical practice a decade ago, immune checkpoint inhibitors
(ICIs) have had an overwhelming impact on cancer treatment. Use of these agents in …

Renal toxicities have been increasingly recognized as complications of the immune
checkpoint inhibitors (ICIs). Recent studies have outlined the incidence and potential risk …

Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment but are associated
with significant autoimmune endocrinopathies that pose both diagnostic and treatment …

Acute kidney injury (AKI) is a common clinical condition among patients admitted in the
hospitals. The condition is associated with both increased short-term and long-term …